Browse the evidence

Initiation of semaglutide was significantly associated with a -3.8% reduction in weight at 13 to 24 months.

Semaglutide may be an effective option for weight management in adults.

Patients can achieve significant weight reduction with the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) compared with placebo when combined with a reduced-calorie diet and increased physical activity.

Practitioners should consider prescribing NB-ER for patients with obesity who are also engaging in dietary and physical activity changes.

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.

Gewichtsreduktion senkt die Konversion eines Prädiabetes in einen Typ-2-Diabetes um 58 % durch Lebensstilintervention.

Praktiker sollten Lebensstilinterventionen zur Gewichtsreduktion empfehlen, um das Risiko für Typ-2-Diabetes zu senken.

Eine Gewichtsreduktion von 10 kg senkt die Gesamtmortalität bei Menschen mit Typ-2-Diabetes um 25 %.

Gewichtsreduktion sollte als Strategie zur Verbesserung der Lebensdauer bei Diabetikern gefördert werden.

Eine Gewichtsreduktion verbessert Blutzuckerwerte und nahezu alle Komorbiditäten des Diabetes.

Ärzte sollten Gewichtsreduktion als Teil der Behandlung von Diabetes und seinen Komorbiditäten empfehlen.

Tirzepatide is effective in glucose control and weight reduction.

Tirzepatide can be considered a viable option for improving glycemic control and aiding weight loss in diabetic patients.

A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.

Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Tirzepatide is effective in reducing body weight and controlling blood glucose levels.

Tirzepatide can be considered a viable treatment option for patients struggling with weight and blood glucose management.

Tirzepatide has been approved by the FDA for treating T2D and managing chronic weight in overweight or obese patients.

Healthcare providers can confidently prescribe tirzepatide for eligible patients based on FDA approval.

Resistance training volume is suggested to be one of the most effective variables for developing muscular hypertrophy.

Practitioners should consider resistance training volume as a key factor in designing hypertrophy-focused training programs.

Controlling for each individual's previous training volume could improve the precision of the muscle hypertrophic response to resistance training.

Practitioners should assess an individual's training history to tailor resistance training programs for optimal muscle growth.

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Supplemental protein hydrolysate had a positive effect on fat-free mass (FFM) with a standardized mean difference (SMD) of 0.36 (95% CI: 0.16–0.56, P = 0.000).

Practitioners may consider recommending protein hydrolysate supplementation to enhance fat-free mass in resistance-trained individuals.

Supplemental protein hydrolysate had a positive effect on lower body strength with a standardized mean difference (SMD) of 0.43 (95% CI: 0.16–0.69, P = 0.001).

Practitioners may consider recommending protein hydrolysate supplementation to enhance lower body strength in resistance-trained individuals.

Velocity-based training (VBT) at 2 or 3 days per week significantly improves muscle morphology in patients with Parkinson's disease.

Practitioners can implement VBT in exercise programs for patients with Parkinson's disease to enhance muscle morphology.

VBT improves neuromuscular performance and functional capability in patients with Parkinson's disease.

Incorporating VBT can enhance both performance and functional abilities in Parkinson's patients.

Improvements in maximal gait speed require a frequency of 3 days per week of VBT.

To maximize gait speed improvements, practitioners should recommend VBT at 3 days per week for Parkinson's patients.

Protein sources and physical activity were positively associated with lean mass in males and/or females.

Encouraging high-quality protein sources and physical activity is beneficial for maintaining lean mass in both sexes.

Current guidelines recommend a healthier lifestyle for all CV risk categories.

Healthcare providers should promote lifestyle changes as a preventive measure for cardiovascular disease.

Lifestyle interventions can reduce the incidence of myocardial infarction and the risk of developing type 2 diabetes.

Encouraging lifestyle changes can significantly lower the risk of serious health issues like heart attacks and diabetes.

Moderate resistance training volume (3 sets per exercise) resulted in larger increases in muscle cross-sectional area (5.2% vs. 3.7%) and strength (3.4-7.7% difference) compared to low volume (1 set).

Practitioners should consider moderate training volume to enhance muscle growth and strength in untrained individuals.

Fifteen participants displayed robust benefits of moderate-volume training on muscle hypertrophy, associated with greater total RNA accumulation.

Identifying individuals who respond well to moderate training volume can help tailor training programs for better hypertrophy outcomes.